Oscillatory Positive Expiratory Pressure (oPEP) Treatment in Chronic Obstructive Pulmonary Disease

Svenningsen, Sarah; Kirby, Miranda; Suggett, Jason; Kanhere, Nikhil; Hasany, Aasim; McCormack, David G.; Párraga, Grace

doi:10.1378/chest.1698587

Cited by 8 publications

(9 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The authors postulated that with greater sputum clearance and cough control, exercise capacity may also improve. Unlike MURRAY et al [30], MUNOZ et al [35], SVENNINGSEN et al [53] and SVENNINGSEN et al [64] did not observe any improvement in the 6MWT.…”

Section: Exercise Capacitymentioning

confidence: 75%

“…Similarly, a longer term study by MUNOZ et al [35] reported an improvement in SGRQ total score when using ELTGOL compared with placebo. Two short-term studies by SVENNINGSEN and co-workers [53,64] reported varying results on SGRQ. In a mixed cohort of COPD and bronchiectasis, 3 weeks of daily Aerobika use improved quality of life (measured using SGRQ) [53].…”

Section: St George's Respiratory Questionnairementioning

confidence: 99%

See 1 more Smart Citation

Measuring airway clearance outcomes in bronchiectasis: a review

et al. 2020

View full text Add to dashboard Cite

While airway clearance techniques (ACTs) are recommended for individuals with bronchiectasis, many trials have demonstrated inconsistent benefits or failed to reach their primary outcome. This review determined the most common clinical and patient-reported outcome measures used to evaluate the efficacy of ACTs in bronchiectasis. A literature search of five databases using relevant keywords and filtering for studies published in English, up until the end of August 2019, was completed. Studies included randomised controlled trials, using crossover or any other trial design, and abstracts. Studies were included where the control was placebo, no intervention, standard care, usual care or an active comparator. Adults with bronchiectasis not related to cystic fibrosis were included. Extracted data comprised study authors, design, duration, intervention, outcome measures and results. The search identified 27 published studies and one abstract. The most common clinical outcome measures were sputum volume (n=23), lung function (n=17) and pulse oximetry (n=9). The most common patient-reported outcomes were health-related quality of life (measured with St George's Respiratory Questionnaire, n=4), cough-related quality of life (measured with Leicester Cough Questionnaire, n=4) and dyspnoea (measured with Borg/modified Borg scale, n=8). Sputum volume, lung function, dyspnoea and health- and cough-related quality of life appear to be the most common clinical and patient-reported measures of airway clearance treatment efficacy.

show abstract

Section: Exercise Capacitymentioning

confidence: 75%

Section: St George's Respiratory Questionnairementioning

confidence: 99%

Measuring airway clearance outcomes in bronchiectasis: a review

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Drug-free airway clearance methods such as oscillating positive expiratory pressure (OPEP) have been proposed to provide benefit in COPD patients though opening and vibrating airways and mobilizing bronchial secretions with increased sputum [13]. Aerobika (TMI, London, ON) is a handheld mechanical OPEP device where patients exhale against a manually adjusted variable resistance.…”

Section: Introductionmentioning

confidence: 99%

A Real-World Study of 30-Day Exacerbation Outcomes in Chronic Obstructive Pulmonary Disease (COPD) Patients Managed with Aerobika OPEP

Burudpakdee

Seetasith

Dunne³

et al. 2017

Pulm Ther

Self Cite

View full text Add to dashboard Cite

“…Another study found that the Aerobika OPEP device resulted in a direct medical cost savings of $553 per patient [20]. These data suggest that the reductions in healthcare resource use and costs associated with the Aerobika OPEP device among postoperative patients in our study may result from the beneficial effects of this device on improving airway structure and function [16,17], thus reducing the risk of developing a PPC that warrants rehospitalization.…”

Section: Discussionmentioning

confidence: 54%

“…Clinical trial results have demonstrated that use of the Aerobika OPEP device significantly improves dyspnea, quality of life, exercise capacity and ease in bringing up sputum in patients with COPD and bronchiectasis [16]. In another clinical trial, the Aerobika OPEP device was further shown to significantly improve ventilation in patients with COPD [17].…”

Section: Introductionmentioning

confidence: 99%

A Real-World Evidence Study Assessing the Impact of Adding the Aerobika Oscillating Positive Expiratory Pressure Device to Standard of Care Upon Healthcare Resource Utilization and Costs in Post-Operative Patients

et al. 2018

Self Cite

View full text Add to dashboard Cite

Introduction The aim of this real-world study was to measure the benefit of the Aerobika oscillating positive expiratory pressure (OPEP) device when added to standard of care (defined as incentive spirometry [IS]) for post-operative patients. Methods Adults aged ≥ 18 years who were hospitalized for cardiac, thoracic or upper abdominal surgery between 1 September 2013 and 30 April 2017 were identified from IQVIA’s Hospital Charge Detail Master (CDM) database; the index date was the date of the first hospitalization for surgery. The control cohort (IS) included patients who had ≥ 1 CDM record within 12 months prior to the index date and ≥ 1 record after discharge, evidence of IS use during index hospitalization and no evidence of use of a PEP or OPEP device at any time during the study period. The Aerobika OPEP cohort was selected in a similar manner, except that patients were required to have evidence of Aerobika OPEP use during the index hospitalization. Aerobika OPEP patients were 1:1 matched to IS patients using propensity score (PS) matching. Hospital readmissions and costs were measured at 30 days post-discharge from the index hospitalization. Results After PS matching, 144 patients were included in each cohort. At 30 days post-discharge, compared to the control (IS) cohort there were significantly fewer patients in the Aerobika OPEP cohort with ≥ 1 all-cause re-hospitalizations (13.9 vs. 22.9%; p = 0.042). The patients in the Aerobika OPEP cohort also had a shorter mean length of stay (± standard deviation) (1.25 ± 4.04 vs. 2.60 ± 8.24 days; p = 0.047) and lower total unadjusted mean all-cause cost per patient ($3670 ± $13,894 vs. $13,775 ± $84,238; p = 0.057). Adjusted analyses suggested that hospitalization costs were 80% lower for the Aerobika OPEP cohort versus the IS cohort (p = 0.001). Conclusion Our results suggest that the addition of the Aerobika OPEP device to standard of care (IS) is beneficial in the post-operative setting. Funding Trudell Medical International.

show abstract

Oscillatory Positive Expiratory Pressure (oPEP) Treatment in Chronic Obstructive Pulmonary Disease

Cited by 8 publications

References 0 publications

Measuring airway clearance outcomes in bronchiectasis: a review

Measuring airway clearance outcomes in bronchiectasis: a review

A Real-World Study of 30-Day Exacerbation Outcomes in Chronic Obstructive Pulmonary Disease (COPD) Patients Managed with Aerobika OPEP

A Real-World Evidence Study Assessing the Impact of Adding the Aerobika Oscillating Positive Expiratory Pressure Device to Standard of Care Upon Healthcare Resource Utilization and Costs in Post-Operative Patients

Contact Info

Product

Resources

About